

Breakthrough urine liquid biopsy prostate cancer test launches in Singapore

March 29, 2022 | News

High demand seen for effective disease management platform for second most common cancer in Singaporean men



miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, have announced the signing of a collaboration agreement to partner in the commercial launch of the award-winning miR Sentinel™ Prostate Cancer Test in Singapore and Southeast Asia.

The miR Sentinel Prostate Cancer Test is a standalone, non-invasive liquid biopsy urine test that can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the malignancy. The proprietary high-throughput technology is based on the interrogation of small noncoding RNAs (sncRNAs) extracted from urinary exosomes and was shown in clinical studies to detect and classify clinically significant prostate cancer with over 90% accuracy. Based on these results, the U.S. Food & Drug Administration granted the test a Breakthrough Device Designation.

In advance of a commercial deployment of the technology in Singapore, the parties agreed to work together to facilitate a local clinical validation study in cooperation with leading local academic medical institutions. The study will be designed to further establish the performance characteristics of the miR Sentinel™ Prostate Cancer Test in the local market.

miR Scientific and LHC plan to commence operation of the partnership and introduce the technology in Singapore during the second quarter of 2022.